College students develop new cancer drugs

Recently, at the closing ceremony of the second Dongguan University Students' science and Technology Innovation Festival, the university students' team of Guangdong Medical University, after two years of large-scale experiments, synthesized ru1, which has good anti-cancer effect and little side effects, has attracted wide attention Based on this, the team won the only first prize in the second Dongguan University Students' science and Technology Innovation Festival innovation and entrepreneurship competition, and won 100000 yuan It is reported that the team consists of four undergraduates and three postgraduates According to the team leader, ruthenium is a rare metal element, and also the cheapest one of the rare metal elements At present, the main research is to treat lung cancer The research direction of the team members is anti-tumor mechanism research According to Lai Guohua, team leader and junior of clinical medicine major, the team has mastered a complete set of laboratory process at present The core technology is mainly composed of seven groups of core experiments, including in vitro anti value-added activity experiment, ru1 effect on cell cycle, mitochondrial, intracellular ROS content, animal experiment, etc Lai Guohua said that compared with the widely used anticancer drugs on the market, the products developed by the project have stronger anticancer function and little side effects There is no relevant research report at home and abroad, which is original The instructor of the team is Chen Meilan, associate professor of Guangyi University In recent five years, she has published 12 papers as the first author or corresponding author, 9 of which are included in SCI At present, the research and development achievements of the team have also been published in the international authoritative SCI Journal oncotarget The early research papers have been employed by the core journal chemical research and application, and the anti-tumor related application research of ruthenium complexes is also applying for patents The drug will soon go to the Affiliated Hospital of Guangdong Medical University to carry out clinical medicine, which is expected to bring good news to cancer patients.